Revenue

EBITDA

Earnings

Price per share at the end of the period divided by the last reported earnings

Free Cash Flow

Biomea Fusion, Inc., a biopharmaceutical company, focuses on the discovery and development of covalent small molecule drugs to treat patients with genetically defined cancers and metabolic diseases. Its lead product candidate is BMF-219, an orally bioavailable, potent, and selective covalent inhibitor of menin, a transcriptional regulator in oncogenic signaling in multiple cancers. The company was incorporated in 2017 and is headquartered in Redwood City, California.

Biomea Fusion, Inc.

The significance of a company's longevity in the market

Years since IPO

Evaluation of recent trends and improvements in the company's revenue

Revenue Growth

Assessment of recent increases in earnings per share, indicating profitability

EPS Growth

Review of the company's ability to generate free cash flow over recent periods

FCF Growth

Analysis of Return on Equity, showing how effectively the company uses equity to generate profits

Examination of debt levels using Debt/Assets and Debt/EBITDA to ensure manageable leverage

Debt

SAN CARLOS, CALIF., NOV. 05, 2025 (GLOBE NEWSWIRE) -- BIOMEA FUSION, INC. (BIOMEA, BIOMEA FUSION OR THE COMPANY) (NASDAQ: BMEA), A CLINICAL-STAGE DIABETES AND OBESITY MEDICINES COMPANY, TODAY ANNOUNCED THE PRESENTATION OF TWO LATE BREAKING POSTERS AT OBESITYWEEK 2025 IN ATLANTA, GEORGIA.

BIOMEA FUSION SHOWCASES PRECLINICAL ADVANCES FOR BMF-650 AND ICOVAMENIB WITH LOW DOSE SEMAGLUTIDE AT OBESITYWEEK 2025

ADVANCES DIABETES AND OBESITY PROGRAMS WITH ICOVAMENIB DEMONSTRATING DURABLE 52-WEEK PHASE II DATA AND WITH BMF-650, BIOMEA'S NEXT-GENERATION, ORAL SMALL MOLECULE GLUCAGON-LIKE PEPTIDE-1 (GLP-1) RECEPTOR AGONIST (RA), DOSING ITS FIRST PATIENT IN A PHASE I CLINICAL TRIAL PRESENTED PRECLINICAL ACTIVITY OF ICOVAMENIB IN COMBINATION WITH SEMAGLUTIDE IN TYPE 2 DIABETES (T2D) ANIMAL MODEL AT EASD ANNUAL MEETING, DEMONSTRATING ENHANCED GLYCEMIC CONTROL AND BODY WEIGHT REDUCTION WITH PRESERVATION OF LEAN MASS RAISED APPROXIMATELY $68 MILLION IN GROSS PROCEEDS THROUGH TWO PUBLIC OFFERINGS, EXTENDING PROJECTED CASH RUNWAY INTO THE FIRST QUARTER OF 2027 SAN CARLOS, CALIF., NOV. 04, 2025 (GLOBE NEWSWIRE) -- BIOMEA FUSION, INC. (BIOMEA OR BIOMEA FUSION OR THE COMPANY) (NASDAQ: BMEA), A CLINICAL-STAGE DIABETES AND OBESITY COMPANY, TODAY REPORTED ITS FINANCIAL RESULTS FOR THE THIRD QUARTER ENDED SEPTEMBER 30, 2025, AND PROVIDED A BUSINESS UPDATE.

BIOMEA FUSION REPORTS THIRD QUARTER 2025 FINANCIAL RESULTS AND CORPORATE HIGHLIGHTS

SAN CARLOS, CALIF., OCT. 30, 2025 (GLOBE NEWSWIRE) -- BIOMEA FUSION, INC. (BIOMEA) (NASDAQ: BMEA), A CLINICAL-STAGE DIABETES AND OBESITY MEDICINES COMPANY, TODAY ANNOUNCED THAT IT WILL PRESENT POSTER PRESENTATIONS AT OBESITYWEEK 2025, TAKING PLACE NOVEMBER 4-7, 2025 IN ATLANTA, GEORGIA.

BIOMEA FUSION TO PRESENT POSTER PRESENTATIONS AT OBESITYWEEK2025

SAN CARLOS, CALIF., OCT. 27, 2025 (GLOBE NEWSWIRE) -- BIOMEA FUSION, INC. (BIOMEA, BIOMEA FUSION OR THE COMPANY) (NASDAQ: BMEA), A CLINICAL-STAGE DIABETES AND OBESITY MEDICINES COMPANY, TODAY ANNOUNCED THAT THE FIRST PATIENT HAS BEEN DOSED IN A PHASE I CLINICAL TRIAL OF BMF-650, THE COMPANY'S INVESTIGATIONAL, NEXT-GENERATION ORAL SMALL MOLECULE GLUCAGON-LIKE PEPTIDE-1 (GLP-1) RECEPTOR AGONIST (RA).

BIOMEA FUSION ANNOUNCES FIRST PATIENT DOSED IN PHASE I STUDY OF BMF-650 A NEXT-GENERATION ORAL GLP-1 RECEPTOR AGONIST

SAN CARLOS, CALIF., OCT. 21, 2025 (GLOBE NEWSWIRE) -- BIOMEA FUSION, INC. (BIOMEA) (NASDAQ: BMEA), A CLINICAL-STAGE DIABETES AND OBESITY COMPANY, TODAY ANNOUNCED THAT IT WILL PARTICIPATE IN CITI'S SMID BIOTECH C-SUITE FIRESIDE CHAT SERIES ON THURSDAY, OCTOBER 23, 2025, AT 8:00 A.M. PACIFIC TIME / 11:00 A.M. EASTERN TIME.

BIOMEA FUSION TO PARTICIPATE IN CITI'S SMID BIOTECH C-SUITE FIRESIDE CHAT SERIES

SAN CARLOS, CALIF., OCT. 07, 2025 (GLOBE NEWSWIRE) -- BIOMEA FUSION, INC. (BIOMEA) (NASDAQ: BMEA), A CLINICAL-STAGE DIABETES AND OBESITY COMPANY, TODAY ANNOUNCED THE PRICING OF ITS PREVIOUSLY ANNOUNCED UNDERWRITTEN PUBLIC OFFERING CONSISTING OF (I) 11,195,121 SHARES OF ITS COMMON STOCK AND ACCOMPANYING WARRANTS TO PURCHASE AN AGGREGATE OF 11,195,121 SHARES OF COMMON STOCK (OR PRE-FUNDED WARRANTS IN LIEU THEREOF) AND (II) IN LIEU OF COMMON STOCK, TO CERTAIN INVESTORS, PRE-FUNDED WARRANTS TO PURCHASE AN AGGREGATE OF UP TO 1,000,000 SHARES OF ITS COMMON STOCK AND ACCOMPANYING WARRANTS TO PURCHASE AN AGGREGATE OF UP TO 1,000,000 SHARES OF COMMON STOCK (OR PRE-FUNDED WARRANTS IN LIEU THEREOF), AT AN EXERCISE PRICE OF $0.0001 PER PRE-FUNDED WARRANT. IN ADDITION, BIOMEA HAS GRANTED THE UNDERWRITERS A 30-DAY OPTION TO PURCHASE UP TO AN ADDITIONAL 1,829,268 SHARES OF COMMON STOCK AND/OR WARRANTS TO PURCHASE 1,829,268 SHARES OF COMMON STOCK AT THE PUBLIC OFFERING PRICE, LESS UNDERWRITING DISCOUNTS AND COMMISSIONS. THE COMMON STOCK AND PRE-FUNDED WARRANTS ARE BEING SOLD IN COMBINATION WITH AN ACCOMPANYING WARRANT TO PURCHASE ONE SHARE OF COMMON STOCK (OR A PRE-FUNDED WARRANT IN LIEU THEREOF) ISSUED FOR EACH SHARE OF COMMON STOCK OR PRE-FUNDED WARRANT SOLD. THE ACCOMPANYING WARRANT HAS AN EXERCISE PRICE OF $2.50 PER SHARE, IS IMMEDIATELY EXERCISABLE FROM THE DATE OF ISSUANCE AND WILL EXPIRE THREE YEARS FROM THE DATE OF ISSUANCE. THE COMBINED OFFERING PRICE OF EACH SHARE OF COMMON STOCK AND ACCOMPANYING COMMON STOCK WARRANT IS $2.05. THE COMBINED OFFERING PRICE OF EACH PRE-FUNDED WARRANT AND ACCOMPANYING COMMON STOCK WARRANT IS $2.0499.

BIOMEA FUSION ANNOUNCES PRICING OF PUBLIC OFFERING OF SECURITIES

SAN CARLOS, CALIF., OCT. 06, 2025 (GLOBE NEWSWIRE) -- BIOMEA FUSION, INC. (BIOMEA) (NASDAQ: BMEA), A CLINICAL-STAGE DIABETES AND OBESITY COMPANY, ANNOUNCED TODAY THAT IT HAS COMMENCED AN UNDERWRITTEN PUBLIC OFFERING OF SHARES OF ITS COMMON STOCK AND ACCOMPANYING WARRANTS TO PURCHASE SHARES OF ITS COMMON STOCK (OR PRE-FUNDED WARRANTS IN LIEU THEREOF) AND, IN LIEU OF COMMON STOCK TO CERTAIN INVESTORS, PRE-FUNDED WARRANTS TO PURCHASE SHARES OF ITS COMMON STOCK AND ACCOMPANYING WARRANTS TO PURCHASE SHARES OF ITS COMMON STOCK (OR PRE-FUNDED WARRANTS IN LIEU THEREOF). IN ADDITION, BIOMEA INTENDS TO GRANT THE UNDERWRITERS A 30-DAY OPTION TO PURCHASE UP TO AN ADDITIONAL FIFTEEN PERCENT (15%) OF THE SHARES OF COMMON STOCK AND/OR WARRANTS TO PURCHASE SHARES OF COMMON STOCK IN THE PROPOSED OFFERING. ALL OF THE SHARES, PRE-FUNDED WARRANTS AND ACCOMPANYING COMMON STOCK WARRANTS TO BE SOLD IN THE PROPOSED OFFERING ARE TO BE SOLD BY BIOMEA.

BIOMEA FUSION ANNOUNCES PROPOSED PUBLIC OFFERING OF SECURITIES

SAN CARLOS, CALIF., OCT. 06, 2025 (GLOBE NEWSWIRE) -- BIOMEA FUSION, INC. (BIOMEA OR BIOMEA FUSION OR THE COMPANY) (NASDAQ: BMEA), A CLINICAL-STAGE DIABETES AND OBESITY COMPANY, TODAY ANNOUNCED POSITIVE 52-WEEK RESULTS FROM ITS PHASE II COVALENT-111 STUDY EVALUATING THE EFFICACY, SAFETY, AND TOLERABILITY OF ICOVAMENIB IN PATIENTS WITH TYPE 2 DIABETES (T2D).

BIOMEA FUSION ANNOUNCES POSITIVE 52-WEEK RESULTS FROM PHASE II COVALENT-111 STUDY IN TYPE 2 DIABETES DEMONSTRATING NON-CHRONIC TREATMENT WITH ICOVAMENIB BENEFITS TWO DISTINCT PATIENT POPULATIONS

SAN CARLOS, CALIF., OCT. 01, 2025 (GLOBE NEWSWIRE) -- BIOMEA FUSION, INC. (BIOMEA OR THE COMPANY) (NASDAQ: BMEA), A CLINICAL-STAGE DIABETES AND OBESITY MEDICINES COMPANY, TODAY ANNOUNCED THAT ON SEPTEMBER 24, 2025, THE COMPENSATION COMMITTEE OF BIOMEA'S BOARD OF DIRECTORS GRANTED ONE NEW EMPLOYEE NON-QUALIFIED STOCK OPTIONS TO PURCHASE 48,000 SHARES OF THE COMPANY'S COMMON STOCK.

BIOMEA FUSION, INC. REPORTS INDUCEMENT GRANT UNDERNASDAQ LISTING RULE 5635(C)(4)

IN A RODENT MODEL OF T2D, ICOVAMENIB IN COMBINATION WITH LOW-DOSE SEMAGLUTIDE PROMOTED ENHANCED GLYCEMIC CONTROL AND BODY WEIGHT REDUCTION WITH PRESERVATION OF LEAN MASS, OUTPERFORMING THE GROUP GIVEN SEMAGLUTIDE ALONE. U.S. FOOD AND DRUG ADMINISTRATION (FDA) CLEARANCE OF THE INVESTIGATIONAL NEW DRUG APPLICATION (IND) FOR BMF-650, BIOMEA'S NEXT-GENERATION INVESTIGATIONAL ORAL GLUCAGON-LIKE-PEPTIDE-1 (GLP-1) RECEPTOR AGONIST (RA), WAS RECENTLY RECEIVED.

BIOMEA FUSION PRESENTS DATA DEMONSTRATING ENHANCED PRECLINICAL ACTIVITY OF ICOVAMENIB IN COMBINATION WITH SEMAGLUTIDE IN TYPE 2 DIABETES (T2D) ANIMAL MODEL AT THE 61ST EASD ANNUAL MEETINGAND PROVIDES ADDITIONAL CORPORATE UPDATE

SAN CARLOS, CALIF., AUG. 05, 2025 (GLOBE NEWSWIRE) -- BIOMEA FUSION, INC. (BIOMEA OR BIOMEA FUSION OR THE COMPANY) (NASDAQ: BMEA), A CLINICAL-STAGE DIABETES AND OBESITY COMPANY, TODAY REPORTED ITS FINANCIAL RESULTS FOR THE SECOND QUARTER ENDED JUNE 30, 2025, AND PROVIDED A BUSINESS UPDATE.

BIOMEA FUSION REPORTS SECOND QUARTER 2025 FINANCIAL RESULTS AND CORPORATE HIGHLIGHTS

SAN CARLOS, CALIF., JULY 24, 2025 (GLOBE NEWSWIRE) -- BIOMEA FUSION, INC. (BIOMEA, BIOMEA FUSION OR THE COMPANY) (NASDAQ: BMEA), A CLINICAL-STAGE DIABETES AND OBESITY MEDICINES COMPANY, TODAY ANNOUNCED THE APPOINTMENT OF JULIANNE AVERILL TO ITS BOARD OF DIRECTORS (THE BOARD), EFFECTIVE JULY 22, 2025.

Biomea Fusion, Inc.

BMEA

Price

Financials Overview

Financial Reports

No items found.

Press Releases

Biomea Fusion, Inc.

BMEA.css-1jgtvd5{-webkit-user-select:none;-moz-user-select:none;-ms-user-select:none;user-select:none;width:1em;height:1em;overflow:hidden;display:inline-block;text-align:center;-webkit-flex-shrink:0;-ms-flex-negative:0;flex-shrink:0;font-size:1.5rem;}

Price

Financials Overview

Financial Reports

No items found.

Press Releases

BMEA